IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 23.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,103 shares of the medical research company's stock after selling 86,910 shares during the quarter. Rockefeller Capital Management L.P. owned approximately 0.16% of IQVIA worth $56,622,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Norges Bank bought a new position in IQVIA during the fourth quarter worth $336,041,000. Raymond James Financial Inc. acquired a new position in IQVIA in the 4th quarter valued at about $236,120,000. American Century Companies Inc. grew its stake in IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after buying an additional 905,960 shares during the last quarter. Invesco Ltd. lifted its position in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Truist Financial cut their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Price Performance

Shares of NYSE:IQV traded down $4.78 during trading on Friday, hitting $143.66. 3,302,597 shares of the company's stock were exchanged, compared to its average volume of 1,403,069. The business's 50-day simple moving average is $177.57 and its 200 day simple moving average is $197.47. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The company has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.